Breaking News Instant updates and real-time market news.

HOOK

Hookipa Pharma

$6.66

-0.09 (-1.33%)

, TGE

Tallgrass Energy

$21.99

0.27 (1.24%)

18:58
07/11/19
07/11
18:58
07/11/19
18:58

Fly Intel: After Hours Movers

HIGHER: Hookipa (HOOK) up 40.0% after disclosing FDA clearance of IND application for HB-201 clinical trial... Tallgress Energy (TGE) up 1.8% after raising dividend. DOWN AFTER EARNINGS: Illumina (ILMN) down 16.0% after below-consensus Q2 guidance and cutting FY19 outlook. Emcore (EMKR) down 15.8% after cutting Q2 guidance... Synacor (SYNC) down 11.2% after saying AT&T switching to new portal provider for ATT.net... Brookfield Infrastructure Partners (BIP) down 3.2% after quity offering... Spirit Airlines (SAVE) down 3.0% after Q2 guidance. ALSO LOWER: SenesTech (SNES) down 18.0% after equity offering... Innovative Industrial Properties (IIPR) down 5.0% after equity offering... Colgate-Palmolive (CL) down 0.5% after buying Filorga Cosmetiques skin care unit for $1.7B. Movers as of 18:45ET.

HOOK

Hookipa Pharma

$6.66

-0.09 (-1.33%)

TGE

Tallgrass Energy

$21.99

0.27 (1.24%)

ILMN

Illumina

$363.55

-9.15 (-2.46%)

EMKR

Emcore

$3.26

-0.09 (-2.69%)

SYNC

Synacor

$1.51

-0.035 (-2.27%)

BIP

Brookfield Infrastructure

$43.95

-0.64 (-1.44%)

SAVE

Spirit Airlines

$52.21

0.77 (1.50%)

SNES

SenesTech

$1.53

-0.205 (-11.85%)

IIPR

Innovative Industrial Properties

$137.76

5.665 (4.29%)

CL

Colgate-Palmolive

$73.89

0.4 (0.54%)

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 29

    Jul

  • 02

    Aug

  • 06

    Aug

  • 08

    Aug

  • 03

    Sep

  • 12

    Sep

  • 13

    Nov

  • 12

    Jul

  • 12

    Jul

  • 12

    Jul

HOOK Hookipa Pharma
$6.66

-0.09 (-1.33%)

05/13/19
BOFA
05/13/19
INITIATION
BOFA
Buy
Hookipa Pharma initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated Hookipa Pharma with a Buy and $17 price target saying it is leveraging arenavirus to develop broad, antigen-specific immune responses to deliver antigens to dendritic cells in the blood. Huang said Hookipa has a broad intellectual property position and this arenavirus segment potentially provides an endless combination of full-length antigens that can direct immune responses to a broad range of diseases.
05/13/19
RBCM
05/13/19
INITIATION
Target $23
RBCM
Outperform
Hookipa Pharma initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated Hookipa Pharma with an Outperform rating and a price target of $23. The analyst believes that the vaccines from the company's arenavirus platform could yield an "optimal immune upregulation" in the treatment and prevention of infectious diseases, and expects these to "drive considerable long-term value as they mature." Abrahams also cites the platform's "validation" in Hookipa's partnership with Gilead that should lead to "monetization" of the company's technology.
TGE Tallgrass Energy
$21.99

0.27 (1.24%)

04/02/19
04/02/19
DOWNGRADE
Target $26

Neutral
Tallgrass Energy cut to Neutral at Goldman Sachs following outperformance
As previously reported, Goldman Sachs analyst Michael Lapides downgraded Tallgrass Energy to Neutral with a price target of $26. The analyst cites the stock's recent outperformance and also warns that its Rockies Express Pipeline natural gas pipeline and Pony Express crude oil pipeline contract roll-offs pose "overhangs", even though the "volume growth out of Bakken, Niobrara, and Powder River Basin could offset this over time". Lapides further notes that Tallgrass Energy's Seahorse and Plaquemines projects could create a financing overhang should they proceed.
04/02/19
GSCO
04/02/19
DOWNGRADE
GSCO
Neutral
Tallgrass Energy downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Michael Lapides downgraded Tallgrass Energy to Neutral with a price target of $26.
04/03/19
04/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Caterpillar (CAT) downgraded to Hold from Buy at Deutsche Bank with analyst Chad Dillard saying the biggest risk to the bull case for Caterpillar is if its backlog growth turns negative, "and it is becoming increasingly clear that it will within this next quarter." 2. Dunkin' Brands (DNKN) downgraded to Market Perform from Outperform at BMO Capital with analyst Andrew Strelzik saying that while he remains positive on the company's underlying fundamentals over the long term, he sees risk/reward at current levels as "less persuasive." 3. Tallgrass Energy (TGE) downgraded to Neutral from Buy at Goldman Sachs with analyst Michael Lapides citing the stock's recent outperformance and also warns that its Rockies Express Pipeline natural gas pipeline and Pony Express crude oil pipeline contract roll-offs pose "overhangs," even though the "volume growth out of Bakken, Niobrara, and Powder River Basin could offset this over time." 4. Walgreens Boots Alliance (WBA) downgraded to Hold from Buy at Loop Capital with analyst Andrew Wolf citing the company's disappointing Q2 earnings and FY19 guidance announced yesterday "driven by significantly lower-than-forecasted gross margin resulting from increased pharmacy reimbursement rate pressure in the U.S." 5. Alcoa (AA) downgraded to Neutral from Buy at BofA/Merrill with analyst Timna Tanners saying she now sees limited free cash flow payments by Alcoa to upstream AWAC joint-venture partner Alumina Ltd, potential excess alumina/bauxite supply, and potential price risks from the Alunorte refinery restarting, the world's largest refinery. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/25/19
SBSH
06/25/19
INITIATION
Target $23
SBSH
Buy
Tallgrass Energy reinstated with a Buy at Citi
Citi analyst Timm Schneider reinstated coverage of Tallgrass Energy (TGE) following the company's transaction with Blackstone (BX) and keeps a Buy rating and $23 price target on the shares. He expects lower volumetric throughput and tariff rates from 2020 onwards given contract expirations amid what may be a challenging re-contracting environment.
ILMN Illumina
$363.55

-9.15 (-2.46%)

07/09/19
PIPR
07/09/19
NO CHANGE
PIPR
Overweight
Illumina checks show strong interest in NovaSeq, says Piper Jaffray
Piper Jaffray analyst William Quirk says his instrument checks suggest little upside from Novaseq systems in Illumina's Q2. However, NovaSeq interest appears to be strong when analyzing search traffic, Quirk tells investors in a research note. The analyst believes consumables growth will drive the company's Q2 results, "powered by large scale projects and oncology." He maintains an Overweight rating on Illumina with a $387 price target.
06/20/19
CANT
06/20/19
NO CHANGE
Target $8
CANT
Neutral
Cantor still expects Pacific Biosciences deal to be approved in Europe
Cantor Fitzgerald analyst Jordan Abrams still expects Illumina's (ILMN) acquisition of Pacific Biosciences (PACB) to be approved in Europe after the Competition and Markets Authority referred the deal to a Phase 2 investigation. The CMA's initial due diligence on anti-competitive concerns was justified, but a better understanding of Pacific Biosciences technology will show that long-read in its current form is a complement, rather than a substitute, to short-read, Abrams tells investors in a research note after hosting an investor call with a competition specialist. He keeps a Neutral rating on Pacific shares with an $8 price target.
06/13/19
CANT
06/13/19
NO CHANGE
Target $8
CANT
Neutral
Cantor sees Pacific Biosciences deal closing despite U.K. probe risk
Cantor Fitzgerald analyst Jordan Abrams points out that the deadline for the U.K.'s Competition and Markets Authority to determine whether or not to move to a Phase 2 investigation on Illumina's (ILMN) proposed buyout of Pacific Biosciences (PACB) is June 18. The analyst's due diligence suggests the acquisition is at risk to move to a Phase 2 investigation, but his view is that the deal will ultimately close. Nonetheless, he expects additional pressure on Pacific Biosciences shares if CMA moves forward with a Phase 2 investigation. Pacific shares last closed at a 19% discount $8 acquisition price, and the deal is still expected to close mid-2019, Abrams tells investors in a research note. He keeps a Neutral rating on Pacific Biosciences.
06/10/19
ADAM
06/10/19
NO CHANGE
Target $30
ADAM
Buy
Illumina price target raised to $360 from $350 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Illumina to $360 from $350 following meeting with management. The analyst said he sees a multi-year path to growth ahead in research and clinical sequencing. He acknowledged there are near-term risks but said he is confident that demand for high-margin sequencing consumables is intact and that the company's commitment to R&D spending coupled with its best in class people, will enable it to maintain its leadership position for years. Massaro reiterated his Buy rating on Illumina shares.
EMKR Emcore
$3.26

-0.09 (-2.69%)

12/06/18
LSCM
12/06/18
NO CHANGE
Target $6
LSCM
Buy
Emcore challenges behind after 'strong' guidance, says Lake Street
Lake Street analyst Jaeson Schmidt reiterates a Buy rating on Emcore with a $6 price target citing the company's "strong" Q1 guidance. The challenges Emcore faced in fiscal 2019 are now behind the company, and it is set to return to "solid" top line growth in fiscal 2019, Schmidt tells investors in a research note. At current valuation multiples, the analyst thinks "there should be a relatively high floor on shares in the near-term."
06/10/19
LSCM
06/10/19
NO CHANGE
LSCM
Emcore acquisition may be being underestimated, says Lake Street
Lake Street analyst Jaeson Schmidt reiterated a Buy rating and $6 price target on Emcore, and raised his FY19 and FY20 estimates on the stock, as a result of the company's acquisition of Squadron Donner Inertial for $25.8M. Schmidt added that he believes investors may be underestimating the impact of the acquisition, as he sees it helping to drive improving earnings leverage.
11/21/18
DADA
11/21/18
NO CHANGE
Target $8
DADA
Buy
Limbach Holding price target lowered to $8 from $15 at DA Davidson
DA Davidson analyst Brent Thielman lowered his price target on Limbach Holdings (LMB) to $8 after its Q3 earnings miss, saying the company has experienced "significant execution challenges in the Mid-Atlantic, culminating into three consecutive quarters of underwhelming profitability". In addition to these issues, the analyst also cites the industry valuation compression. Thielman keeps his Buy rating on Limbach Holdings, noting that "salvage value and recovery potential" exist for this "interesting concoction of growth and mix shift". The analyst further states that Limbach Holdings represents a smaller version of the "very successful" and cash flow-rich Comfort Systems (FIX) and EMCOR (EMKR).
04/02/19
RILY
04/02/19
UPGRADE
Target $5.45
RILY
Buy
Emcore upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst David Kang upgraded Emcore to Buy from Neutral with a $5.45 price target.
SYNC Synacor
$1.51

-0.035 (-2.27%)

11/09/18
RSBL
11/09/18
DOWNGRADE
RSBL
Neutral
Synacor downgraded to Neutral from Buy at Rosenblatt
08/02/18
LSCM
08/02/18
NO CHANGE
Target $3
LSCM
Buy
Synacor shares are 'worth revisiting,' says Lake Street
Lake Street analyst Mark Argento says shares of Synacor (SYNC) are "worth revisiting" as the story becomes less about AT&T (T) and more about higher margin recurring revenues. The company posted another solid quarter, Argento tells investors in a post-earnings research note. He keeps a Buy rating on Synacor with a $3 price target.
BIP Brookfield Infrastructure
$43.95

-0.64 (-1.44%)

07/01/19
STFL
07/01/19
DOWNGRADE
STFL
Hold
Genesee & Wyoming downgraded to Hold from Buy at Stifel
Stifel analyst Michael Baudendistel downgraded Genesee & Wyoming (GWR) to Hold from Buy after the company agreed to be acquired and taken private by Brookfield Infrastructure Partners (BIP) and its institutional partners. The deal requires two-thirds approval by shareholders, but he sees approval as likely given that the acquisition price is a 39.5% premium to where shares traded before media reports regarding a deal, Baudendistel noted.
04/25/19
FBCO
04/25/19
DOWNGRADE
Target $46
FBCO
Neutral
Brookfield Infrastructure downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Andrew Kuske downgraded Brookfield Infrastructure to Neutral from Outperform, with a $46 price target, given the more limited return to target and the balancing of funding needs. The analyst notes that the most interesting near-term issue facing Brookfield Infrastructure Partners is pending close for Brookfield's (BAM) Infrastructure Fund IV likely landing around $20B.
04/25/19
FBCO
04/25/19
DOWNGRADE
FBCO
Neutral
Brookfield Infrastructure downgraded to Neutral from Outperform at Credit Suisse
07/11/19
LEHM
07/11/19
INITIATION
Target $46
LEHM
Equal Weight
Brookfield Infrastructure initiated with an Equal Weight at Barclays
Barclays analyst Moses Sutton started Brookfield Infrastructure Partners with an Equal Weight rating and $46 price target. After nearly a decade of double-digit distribution growth, the company's scale has reached a point where its growth profile is "increasingly re-rating" closer to the bottom of its targeted distribution growth range of 5%-9%, Sutton tells investors in a research note.
SAVE Spirit Airlines
$52.21

0.77 (1.50%)

06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
American, Southwest raised domestic rates in last two days, says JPMorgan
JPMorgan analyst Jamie Baker said American Airlines (AAL) took a "plain vanilla" domestic fare increase of $5 one-way yesterday morning, which was followed by what looks like a system-wide increase from Hawaiian (HA) and a "substantive" Lower 48 increase from Southwest (LUV). He was not expecting another increase so soon after the industry took a broad-based domestic increase in the second week of May, noted Baker, who thinks evidence of domestic demand and potential Q2 guidance increases could reverse "recent apathy" towards the airline space. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Continental (UAL).
06/06/19
06/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qorvo (QRVO) downgraded to Equal Weight from Overweight at Barclays with analyst Blayne Curtis citing the company's higher relative valuation, concerns of increased radio frequency competition, and potential further impacts from the trade war for the downgrade. 2. Spirit Airlines (SAVE) downgraded to Neutral from Buy at Goldman Sachs with analyst Catherine O'Brien saying there is downside risk to the consensus earnings forecasts for Spirit while United's estimates have appropriately incorporated tougher second half 2019 comparables. 3. Orange SA (ORAN) downgraded to Equal Weight from Overweight at Morgan Stanley. 4. Cloudera (CLDR) downgraded two notches to Hold from Strong Buy at Needham, to Neutral from Buy at Citi, to Hold from Buy at Stifel, and to Market Perform from Outperform at Raymond James. 5. FuelCell (FCEL) downgraded to Perform from Outperform at Oppenheimer and to Market Perform from Outperform at Cowen. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/03/19
STFL
07/03/19
NO CHANGE
Target $90
STFL
Buy
Delta one of biggest beneficiaries of longer MAX grounding, says Stifel
Stifel analyst Joseph DeNardi noted that Delta's (DAL) updated Q2 guidance yesterday was "strong across the board," pointing out that domestic load factor for the quarter of 89% benefited from the fact that the grounding of Boeing's (BA) MAX fleet is keeping industry capacity growth constrained. He sees Delta as one of the biggest beneficiaries, second only to Spirit Airlines (SAVE) and Alaska Air (ALK), as the grounding extends further out given the company's lack of exposure and the industry's competitive capacity dynamics. DeNardi maintains a Buy rating and $90 price target on Delta shares.
06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
JPMorgan notes airline fare hike, doesn't see domestic 'resilience' as priced in
JPMorgan analyst Jamie Baker said he was "surprised" to see domestic fares rising again after a price hike five weeks ago, noting that Southwest (LUV) joined with an increase overnight. Given "the crescendo of inquiries as to why, and nary a question on fares," Baker said he is confident that increased domestic fare resilience is not yet priced into airline stocks. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Spirit Airlines (SAVE) and United Continental (UAL).
SNES SenesTech
$1.53

-0.205 (-11.85%)

10/19/18
ROTH
10/19/18
NO CHANGE
Target $2.5
ROTH
Buy
SenesTech label change should open up pro purchasing, says Roth Capital
After SenesTech announced that the EPA has approved the removal of the "Restricted Use Only" label from its ContraPest product, Roth Capital analyst Gerry Sweeney said he believes the change should open up additional pest management professionals to buying the product. Sweeney, who maintains his view that SenesTech would likely be best under the umbrella of a larger specialty chemical or products company, keeps a Buy rating on the shares, adding that ContraPest "could be worth multiples above today's valuation to the right company."
07/13/18
CHLM
07/13/18
NO CHANGE
Target $2
CHLM
Buy
SenesTech's ContraPest registration 'positive,' but expected, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich reiterated a Buy rating and $2 price target on SenesTech after the California Department of Pesticide Regulation officially registered ContraPest for use in California. While he views the registration as a positive and is encouraged by the approval, Ellich says it is not unexpected as he thought the 30-day comment period would prove to be "more of a formality." Ellich notes that his estimates already contemplate a sharp acceleration in revenue based on regulatory approvals and commercial success.
IIPR Innovative Industrial Properties
$137.76

5.665 (4.29%)

03/20/19
LTCO
03/20/19
DOWNGRADE
LTCO
Neutral
Innovative Industrial Properties downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst John Massocca downgraded Innovative Industrial Properties to Neutral from Buy without a price target. The company's "sector leading" growth potential and "unique position" is now reflected in the stock's valuation, Massocca tells investors in a research note. He downgrades the shares following the recent rally.
03/19/19
BTIG
03/19/19
NO CHANGE
Target $101
BTIG
Buy
Innovative Industrial Properties price target raised to $101 from $72 at BTIG
BTIG analyst Thomas Catherwood raised his price target on Innovative Industrial Properties to $101 and kept his Buy rating, saying that while his prior research note in January expressed confidence in the company's position as a "creative capital provider to the cannabis industry", the "investor acceptance of the cannabis sector" was even better than anticipated. The analyst is also positive on the "funding sources available to Innovative Industrial Properties, and the management's ability to source/execute deals", both of which are evolving in a short period of time. With $144M convertible debt offering completed, Catherwood says Innovative Industrial Properties has even more capital to pursue acquisitions in spite of its existing $114M in liquidity.
01/14/19
BTIG
01/14/19
INITIATION
Target $60
BTIG
Buy
Innovative Industrial Properties initiated with a Buy at BTIG
BTIG analyst Thomas Catherwood initiated Innovative Industrial Properties with a Buy rating and a price target of $60, citing the company's attributes of "early cycle" participation in cannabis industry, outsized scale relative to other REITS, and defensive position in a secular - not cyclical - business. The analyst contends that the REIT's "strategy, capital structure, and creative acquisition arrangements", along with its first-mover advantage, give it the runway for sustainable growth.
06/20/19
BTIG
06/20/19
NO CHANGE
Target $148
BTIG
Buy
Innovative Industrial Properties price target raised to $148 from $101 at BTIG
BTIG analyst Thomas Catherwood raised his price target on Innovative Industrial Properties to $148 and kept his Buy rating after the company disclosed an $18M growth capital increase with its Michigan tenant Green Peak yesterday. The analyst notes that the announcement reflects the company's "unique position" to capitalize on a "strategic capital partner" role amid the cannabis industry's "race for growth" trend going forward. Catherwood adds that Green Peak is likely not alone in seeking strategic capital partners to expand cannabis operations in Michigan and Florida.
CL Colgate-Palmolive
$73.89

0.4 (0.54%)

06/11/19
ARGS
06/11/19
NO CHANGE
Target $82
ARGS
Buy
Colgate-Palmolive price target raised to $82 from $72 at Argus
Argus analyst Chris Graja raised his price target on Colgate-Palmolive to $82 and kept his Buy rating. The analyst cites the company's 2.4% dividend yield exceeding the 10-year Treasury note payout and expects that dividend to continue to increase. Graja also points to Colgate-Palmolive's accelerating organic sales growth in Q1 to 3% from 2% in Q4 driven by the management's more aggressive advertising initiatives, greater e-commerce product availability, and the company's high financial strength rating relative to his coverage universe.
04/29/19
04/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew McClintock saying Target is taking market share from a "much weaker" retailer subset than other positive traffic retailers. 2. Sprouts Farmers Market (SFM) upgraded to Buy from Hold at Deutsche Bank. 3. American Airlines (AAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying American's lowering of its earnings guidance range last week was not unexpected given the recent rise in fuel prices and grounding of its MAX fleet. The analyst thinks the resetting of expectations by management establishes a "floor" for American's share price and provides the company a bit more "cushion" around its earnings targets. 4. Colgate-Palmolive (CL) upgraded to Neutral from Underweight at JPMorgan with analyst Andrea Teixeira saying the company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S. 5. Adobe (ADBE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/29/19
JEFF
04/29/19
NO CHANGE
Target $73
JEFF
Hold
Colgate-Palmolive price target raised to $73 from $61 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Colgate-Palmolive to $73 from $61 following the company's "solid" Q1 results. While a recovery in China will take time, Colgate-Palmolive is "importantly seeing progress" across key markets, including the U.S. and Latin America, and the Colgate Total relaunch is progressing in-line with expectations, Grundy tells investors in a research note. He views the company's sales recovery as "encouraging," but thinks the stock's current valuation limits upside potential. As such, he keeps a Hold rating on Colgate-Palmolive.
04/29/19
JPMS
04/29/19
UPGRADE
Target $70
JPMS
Neutral
JPMorgan upgrades Colgate-Palmolive to Neutral on improved sales growth
JPMorgan analyst Andrea Teixeira upgraded Colgate-Palmolive to Neutral from Underweight and raised her price target for the shares to $70 from $62. The company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S., Teixeira tells investors in a research note. For the first time in two years, Colgate-Palmolive delivered both volume and pricing growth when reporting quarterly results on Friday, says the analyst. She notes that while the company's global market share losses on a year-over-year basis are still lingering, its market share has been more stable sequentially.

TODAY'S FREE FLY STORIES

CECE

CECO Environmental

$8.88

0.01 (0.11%)

09:06
07/23/19
07/23
09:06
07/23/19
09:06
Hot Stocks
CECO Environmental announces important new order »

CECO Environmental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 06

    Aug

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

, SPX

S&P 500

$0.00

(0.00%)

09:06
07/23/19
07/23
09:06
07/23/19
09:06
General news
IMF lowers 2019 global growth forecast to 3.2%, 2020 growth view to 3.5% »

The IMF announced that…

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$101.23

0.44 (0.44%)

09:06
07/23/19
07/23
09:06
07/23/19
09:06
Hot Stocks
Medtronic requests approval of non-adjunctive labeling from FDA »

Medtronic announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

AMID

American Midstream Partners

$5.24

(0.00%)

09:03
07/23/19
07/23
09:03
07/23/19
09:03
Hot Stocks
American Midstream Partners completes merger transactions with ArcLight Energy »

American Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:03
07/23/19
07/23
09:03
07/23/19
09:03
General news
FHFA House Price Index M/M change data reported »

May FHFA House Price…

LJPC

La Jolla

$8.54

-0.16 (-1.84%)

09:02
07/23/19
07/23
09:02
07/23/19
09:02
Hot Stocks
La Jolla receives orphan drug designation from FDA for LJPC-0118 »

La Jolla Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$91.23

-0.57 (-0.62%)

09:01
07/23/19
07/23
09:01
07/23/19
09:01
Hot Stocks
Arthur J. Gallagher acquires The Novick Group »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

KO

Coca-Cola

$51.25

-0.15 (-0.29%)

, UTX

United Technologies

$132.94

0.57 (0.43%)

09:00
07/23/19
07/23
09:00
07/23/19
09:00
Hot Stocks
Fly Intel: Pre-market Movers »

UP AFTER EARNINGS:…

KO

Coca-Cola

$51.25

-0.15 (-0.29%)

UTX

United Technologies

$132.94

0.57 (0.43%)

LMT

Lockheed Martin

$357.57

0.675 (0.19%)

CHMA

Chiasma

$6.19

-0.11 (-1.75%)

RLGY

Realogy

$5.17

-0.08 (-1.52%)

SHW

Sherwin-Williams

$454.62

-1.9 (-0.42%)

DGX

Quest Diagnostics

$98.07

-1.175 (-1.18%)

JBLU

JetBlue

$18.96

0.05 (0.26%)

CNC

Centene

$52.19

-0.46 (-0.87%)

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

TTS

Tile Shop

$3.96

-0.12 (-2.94%)

ZION

Zions Bancorp

$45.16

-0.95 (-2.06%)

ACAD

Acadia

$25.97

0.28 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 20

    Aug

  • 09

    Sep

  • 19

    Sep

09:00
07/23/19
07/23
09:00
07/23/19
09:00
General news
U.S. equities are stronger »

U.S. equities are…

EFII

Electronics for Imaging

$36.97

(0.00%)

09:00
07/23/19
07/23
09:00
07/23/19
09:00
Hot Stocks
Electronics for Imaging announces completion of acquisition by Siris affiliate »

Electronics For Imaging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOOO

BRP Inc.

$33.47

-0.85 (-2.48%)

08:58
07/23/19
07/23
08:58
07/23/19
08:58
Hot Stocks
BRP Inc. completes increase to its Term Facility »

BRP announced that in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENG

Phoenix New Media

$2.69

-0.14 (-4.95%)

08:58
07/23/19
07/23
08:58
07/23/19
08:58
Hot Stocks
Phoenix New Media enters into share purchase supplemental agreement »

Phoenix New Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEND

Generation NEXT Franchise Brands

$0.00

(0.00%)

08:57
07/23/19
07/23
08:57
07/23/19
08:57
Hot Stocks
Reis & Ivry's soft serve robotic kiosks aprproved by CDPH »

Generation Next announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DDAIF

Daimler AG

$0.00

(0.00%)

08:57
07/23/19
07/23
08:57
07/23/19
08:57
Hot Stocks
Daimler AG announces investment by China's BAIC Group »

Daimler AG announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:57
07/23/19
07/23
08:57
07/23/19
08:57
General news
Redbook Store Sales data reported »

Week of 7/20 Redbook…

AMID

American Midstream Partners

$5.24

(0.00%)

08:56
07/23/19
07/23
08:56
07/23/19
08:56
Hot Stocks
Breaking Hot Stocks news story on American Midstream Partners »

American Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$51.25

-0.15 (-0.29%)

08:55
07/23/19
07/23
08:55
07/23/19
08:55
Hot Stocks
Breaking Hot Stocks news story on Coca-Cola »

Coca-Cola sees currency…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 19

    Sep

REAL

RealReal

$24.84

0.69 (2.86%)

08:55
07/23/19
07/23
08:55
07/23/19
08:55
Initiation
RealReal initiated at Cowen »

RealReal initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

T

AT&T

$32.14

-0.63 (-1.92%)

, AAPL

Apple

$207.21

4.59 (2.27%)

08:55
07/23/19
07/23
08:55
07/23/19
08:55
Options
Notable open interest changes for July 23rd »

Monday's total…

T

AT&T

$32.14

-0.63 (-1.92%)

AAPL

Apple

$207.21

4.59 (2.27%)

FB

Facebook

$202.32

3.94 (1.99%)

NFLX

Netflix

$310.57

-4.53 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 08

    Aug

LPSN

LivePerson

$32.64

0.45 (1.40%)

08:53
07/23/19
07/23
08:53
07/23/19
08:53
Hot Stocks
Hammer, LivePerson announce integration to provide conversational commerce »

Hammer Fiber Optics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Dec

WLDCF

ICC International Cannabis

$0.00

(0.00%)

, PFE

Pfizer

$42.83

0.05 (0.12%)

08:52
07/23/19
07/23
08:52
07/23/19
08:52
Earnings
ICC International Cannabis, Biotti sign advisory agreement with Alex Makriyannis »

ICC International…

WLDCF

ICC International Cannabis

$0.00

(0.00%)

PFE

Pfizer

$42.83

0.05 (0.12%)

BMY

Bristol-Myers

$42.77

-0.55 (-1.27%)

BIIB

Biogen

$232.46

1.26 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 09

    Sep

  • 16

    Sep

FITB

Fifth Third

$27.84

-0.11 (-0.39%)

08:51
07/23/19
07/23
08:51
07/23/19
08:51
Hot Stocks
Fifth Third sees Q3 NII up 1% from Q2 »

Sees Q3 consumer loans up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

NVS

Novartis

$94.05

0.47 (0.50%)

08:50
07/23/19
07/23
08:50
07/23/19
08:50
Recommendations
Novartis analyst commentary at Argus »

Novartis price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

CE

Celanese

$105.66

-1.35 (-1.26%)

08:50
07/23/19
07/23
08:50
07/23/19
08:50
Recommendations
Celanese analyst commentary at Baird »

Celanese EM volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

NEOG

Neogen

$63.44

-0.58 (-0.91%)

08:46
07/23/19
07/23
08:46
07/23/19
08:46
Earnings
Neogen reports Q4 EPS 30c, consensus 29c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.